Beijing Luzhu Biotechnology Co., Ltd. (2480.HK)

21.950 -0.450 (-2.01%) At close: 11:23AM HKT

Beijing Luzhu Biotechnology Co., Ltd.

No. 3 Guangtong Street
Industrial Development Zone Tongzhou District
Beijing
China
86 10 6156 8561
https://luzhubiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 133

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jian Kong	Co-Founder, GM, CEO, Chief Scientist & Chairman	767.03k	N/A	1964
Ms. Xianmin Jiang	Co-Founder, Deputy GM, Chief Medical Officer & Vice-Chairlady	575.81k	N/A	1963
Ms. Yanping Zhang	Co-Founder, Deputy GM & Executive Director	576.88k	N/A	1963
Ms. Zheng Liu	Chief Financial Officer	N/A	N/A	1987
Ms. Ling Peng	CTO & Supervisor	N/A	N/A	1981
Mr. Chaowei Han	Head of Manufacturing & Engineering	N/A	N/A	1975
Mr. Siyu Liu	Secretary of Board & Joint Company Secretary	N/A	N/A	1991
Ms. Wing Yan Yuen FCIS, FCS	Joint Company Secretary	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. Its clinical-stage product candidates include LZ901, a recombinant herpes zoster vaccine; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection product for the treatment of various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection to treat B cell leukemia and lymphoma. The company's pre-clinical-stage product candidates comprise Recombinant Varicella vaccine for the prevention of varicella in children; Recombinant Syncytial Virus (RSV) vaccine for the indication of RSV-induced lower respiratory tract disease; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932 bispecific antibody to treat lymphoma. The company also offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and haemophilus influenzae Type B polysaccharide IgG antibody detection kits. In addition, it develops meningococcal group A and C polysaccharide conjugate vaccine, meningococcal group A and C and haemophilus influenzae type b conjugate vaccine, group ACYW135 meningococcal polysaccharide vaccine, typhoid polysaccharide vaccine, and tetanus toxoid vaccine. The company was formerly known as Beijing Luzhu Biotech. The company was incorporated in 2001 and is headquartered in Beijing, China.

Corporate governance

Beijing Luzhu Biotechnology Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.